Vaccinia virus (ATCC® VR-2056)

Classification: Poxviridae, Orthopoxvirus  /  Product Format: frozen

Classification Poxviridae, Orthopoxvirus
Deposited As Vaccinia virus, Orthopoxvirus
Agent Vaccinia virus
Strain VTK-79L
Applications
expression vector
Biosafety Level 2
Isolation
The HindIII J-fragment of TK-79 containing a mutant (non-functional) thymidine kinase (TK) gene was cloned into the L-variant vaccinia virus by in vivo recombination.
Product Format frozen
Storage Conditions -70°C
Comments
Vaccination recommended for lab staff manipulating vaccinia, monkeypox, or cowpox viruses (CDC/NIH Biosafety in Microbiological and Biomedical Laboratories, 4th ed, 1999 - stock no. 017-040-00547-4).
A thymidine kinase negative variant of the S-variant of vaccinia strain WR.
This is a thymidine kinase negative (TK-) mutant of the L-variant of vaccinia virus strain WR. Plasmids can be introduced into this mutant by in vivo recombination.
The HindIII J-fragment of TK-79 containing a mutant (non-functional) thymidine kinase (TK) gene was cloned into the L-variant vaccinia virus by in vivo recombination.
Prepared by: E. Paoletti and D. Panicali
Effect on Host
Cytopathic effects (plaque formation) in Vero cells
Effect on Host
Cytopathic effects (plaque formation) in Vero cells
Name of Depositor New York State Department of Health
References

Paoletti E, Panicali D. Modified vaccinia virus. US Patent 4,603,112 dated Jul 29 1986

Paoletti E, Panicali D. Method for immunizing animals with synthetically modified vaccinia virus. US Patent 4,722,848 dated Feb 2 1988

Panicali D, et al. Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J. Virol. 37: 1000-1010, 1981. PubMed: 6262520